{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:46:41Z","timestamp":1760233601832,"version":"build-2065373602"},"reference-count":70,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology International"],"abstract":"<jats:p>Migraine is a neurobiological headache disorder that affects around 16% of adults in the United States. Medical treatment of mild to moderate migraines include non-prescription non-steroidal anti-inflammatory drugs, acetaminophen, or aspirin and caffeine-containing combination analgesics. Additionally, moderate to severe migraines and those that are mild to moderate that have not responded to analgesics can be treated with triptans, which are drugs specific for migraine treatment. Non-pharmacological treatments include cognitive behavioral therapy and relaxation training. Medications for the prevention of migraines have also been developed since they are more affective in offsetting the symptoms. Ubrogepant\u2019s high specificity and selectivity for calcitonin gene-related peptide (CGRP) sets it apart from certain other drugs, which previously limited the treatment of migraines with or without aura due to their decreased selectivity. The most frequently reported side effects are oropharyngeal pain, nasopharyngitis, and headache. Most studies found that participants receiving Ubrogepant were free from pain within 2 h when compared to placebo. Patients taking Ubrogepant should avoid taking it when pregnant or with end stage renal disease. In summary, Ubrogepant has good tolerability and an overall favorable safety profile. It appears to hold promise for the acute treatment of migraines with or without aura in adults.<\/jats:p>","DOI":"10.3390\/neurolint13010004","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T01:22:23Z","timestamp":1611796943000},"page":"32-45","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ubrogepant to Treat Acute Migraine in Adults"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7436-6206","authenticated-orcid":false,"given":"Amber N.","family":"Edinoff","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Austin","family":"Casey","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Colon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa R.","family":"Zaheri","sequence":"additional","affiliation":[{"name":"Shreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney M.","family":"Gregoire","sequence":"additional","affiliation":[{"name":"Shreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret M.","family":"Bourg","sequence":"additional","affiliation":[{"name":"Shreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2464-0187","authenticated-orcid":false,"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica S.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-3322","authenticated-orcid":false,"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel J.","family":"Kaye","sequence":"additional","affiliation":[{"name":"School of medicine, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridhar R.","family":"Tirumala","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA"},{"name":"Department of Anesthesiology, University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA"},{"name":"Department of Anesthesiology, Creighton University School of Medicine, Omaha, NE 68124, USA"},{"name":"Valley Anesthesiology and Pain Consultants\u2014Envision Physician Services, Phoenix, AZ 85004, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-6085","authenticated-orcid":false,"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA"},{"name":"Southcoast Health, Southcoast Physicians Group Pain Medicine, Wareham, MA 02571, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(04)15440-8","article-title":"Migraine","volume":"363","author":"Silberstein","year":"2004","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"ITC49","DOI":"10.7326\/AITC201704040","article-title":"Migraine","volume":"166","author":"MacGregor","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_3","unstructured":"(2020, October 07). Migraine Overview and Summary of Current and Emerging Treatment Options|AJMC. Available online: https:\/\/www.ajmc.com\/view\/migraine-overview-and-summary--of-current-and-emerging-treatment-options."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cologno, D., Mazzeo, A., Lecce, B., Mundi, C., Petretta, V., Casucci, G., and d\u2019Onofrio, F. (2012). Triptans: Over the migraine. Neurol. Sci., Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/22644202\/.","DOI":"10.1007\/s10072-012-1066-1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","article-title":"The pathophysiology of migraine: Implications for clinical management","volume":"17","author":"Charles","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/head.13300","article-title":"A Phase-by-Phase Review of Migraine Pathophysiology","volume":"58","author":"Dodick","year":"2018","journal-title":"Headache"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/head.12026","article-title":"The evolution of a migraine attack\u2014A review of recent evidence","volume":"53","author":"Charles","year":"2013","journal-title":"Headache"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/ana.410280610","article-title":"Timing and topography of cerebral blood flow, aura, and headache during migraine attacks","volume":"28","author":"Olesen","year":"1990","journal-title":"Ann. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","article-title":"Migraine and its psychiatric comorbidities","volume":"87","author":"Minen","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archpsyc.1990.01810210057008","article-title":"Migraine and Psychopathology: Results of the Zurich Cohort Study of Young Adults","volume":"47","author":"Merikangas","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0022-3956(93)90008-P","article-title":"Headache syndromes and psychiatric disorders: Association and familial transmission","volume":"27","author":"Merikangas","year":"1993","journal-title":"J. Psychiatr. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0165-1781(91)90102-U","article-title":"Migraine, psychiatric disorders, and suicide attempts: An epidemiologic study of young adults","volume":"37","author":"Breslau","year":"1991","journal-title":"Psychiatry Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1526-4610.2006.00578.x","article-title":"Headache and sleep disorders: Review and clinical implications for headache management","volume":"46","author":"Rains","year":"2006","journal-title":"Headache"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.55.5.629","article-title":"Migraine, quality of life, and depression: A population-based case-control study","volume":"55","author":"Lipton","year":"2000","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1468-1331.2003.00551.x","article-title":"Depression and anxiety disorders associated with headache frequency. The Nord-Tr\u00f8ndelag Health Study","volume":"10","author":"Zwart","year":"2003","journal-title":"Eur. J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1526-4610.2011.01906.x","article-title":"Childhood abuse and migraine: Epidemiology, sex differences, and potential mechanisms","volume":"51","author":"Tietjen","year":"2011","journal-title":"Headache"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"g1416","DOI":"10.1136\/bmj.g1416","article-title":"Chronic migraine","volume":"348","author":"Schwedt","year":"2014","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1744806918767697","DOI":"10.1177\/1744806918767697","article-title":"Chronic migraine: A process of dysmodulation and sensitization","volume":"14","author":"Su","year":"2018","journal-title":"Mol. Pain"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0072-9752(10)97062-0","article-title":"Vestibular migraine","volume":"97","author":"Strupp","year":"2010","journal-title":"Handb. Clin. Neurol."},{"key":"ref_20","unstructured":"Von Brevern, M., and Lempert, T. (2020, October 07). Vestibular migraine, Handbook of Clinical Neurology, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/27638080\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/head.13379","article-title":"History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment","volume":"58","author":"Tepper","year":"2018","journal-title":"Headache"},{"key":"ref_22","unstructured":"(2020, October 07). Ubrelvy (Ubrogepant) Dosing, Indications, Interactions, Adverse Effects, and More. Available online: https:\/\/reference.medscape.com\/drug\/ubrelvy-ubrogepant-1000348."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Olesen","year":"2018","journal-title":"Cephalalgia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","article-title":"Chronic migraine: Risk factors, mechanisms and treatment","volume":"12","author":"May","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: Epidemiology, Burden, and Comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol. Clin."},{"key":"ref_26","first-page":"344","article-title":"Integrated care for chronic migraine patients: Epidemiology, burden, diagnosis and treatment options","volume":"15","author":"Diener","year":"2015","journal-title":"Clin. Med. J. R. Coll. Physicians Lond."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1474-4422(13)70107-8","article-title":"Vestibular migraine: Clinical aspects and pathophysiology","volume":"12","author":"Furman","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/VES-2012-0453","article-title":"Vestibular migraine: Diagnostic criteria","volume":"22","author":"Lempert","year":"2012","journal-title":"J. Vestib. Res. Equilib. Orientat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11916-018-0735-z","article-title":"Episodic Migraine With and Without Aura: Key Differences and Implications for Pathophysiology, Management, and Assessing Risks","volume":"22","author":"Vgontzas","year":"2018","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11910-018-0845-3","article-title":"Women and Migraine: The Role of Hormones","volume":"18","author":"Todd","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11916-017-0628-6","article-title":"Treatment Update of Chronic Migraine","volume":"21","author":"Cho","year":"2017","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_33","first-page":"33","article-title":"Medical treatment guidelines for preventive treatment of migraine","volume":"26","author":"Huang","year":"2017","journal-title":"Acta Neurol. Taiwanica"},{"key":"ref_34","first-page":"271","article-title":"Treatment of acute migraine headache","volume":"83","author":"Gilmore","year":"2011","journal-title":"Am. Fam. Physician"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in migraine: New drugs, new hope?","volume":"20","author":"Do","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/phar.1876","article-title":"Hormone-Related Migraine Headaches and Mood Disorders: Treatment with Estrogen Stabilization","volume":"37","author":"Warnock","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/head.12640","article-title":"Systematic Review of Preventive and Acute Treatment of Menstrual Migraine","volume":"55","author":"Nierenburg","year":"2015","journal-title":"Headache"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-019-1032-x","article-title":"Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: Findings from SAMURAI and SPARTAN, two randomized phase 3 trials","volume":"20","author":"Loo","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0333102419864132","article-title":"Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)","volume":"39","author":"Brandes","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1526-4610.2006.00376.x","article-title":"Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: Results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study","volume":"46","author":"Goldstein","year":"2006","journal-title":"Headache"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11916-012-0304-9","article-title":"Behavioral therapy for chronic migraine","volume":"17","author":"Pistoia","year":"2013","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.mayocp.2015.01.010","article-title":"Best Practices for Patients with Chronic Migraine: Burden, Diagnosis, and Management in Primary Care","volume":"90","author":"Starling","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ncl.2019.07.003","article-title":"Behavioral Interventions for Migraine","volume":"37","author":"Buse","year":"2019","journal-title":"Neurol. Clin."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ncl.2019.07.006","article-title":"Acute Treatment of Migraine","volume":"37","author":"Tepper","year":"2019","journal-title":"Neurol. Clin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/WNL.0000000000002918","article-title":"Chronic migraine prevention with nVNS: The EVENT study","volume":"87","author":"Silberstein","year":"2016","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1129-2377-14-95","article-title":"Safety and patients\u2019 satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly\u00ae device in headache treatment: A survey of 2,313 headache sufferers in the general population","volume":"14","author":"Magis","year":"2013","journal-title":"J. Headache Pain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/head.12999","article-title":"Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies","volume":"57","author":"Aurora","year":"2017","journal-title":"Headache"},{"key":"ref_48","first-page":"17","article-title":"Migraine Headache Prophylaxis","volume":"99","author":"Ha","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): A multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-020-01264-5","article-title":"Ubrogepant: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_53","unstructured":"Center for Drug Evaluation and Research, FDA (2020, October 07). Ubrogepant FDA, Available online: www.fda.gov\/medwatch."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1358\/dot.2020.56.7.3157311","article-title":"Ubrogepant to treat migraine","volume":"56","author":"Dhir","year":"2020","journal-title":"Drugs Today"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14656566.2020.1721462","article-title":"Ubrogepant for the treatment of migraine","volume":"21","author":"Curto","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_56","unstructured":"(2020, October 07). Ubrogepant\u2014DrugBank. Available online: https:\/\/go.drugbank.com\/drugs\/DB15328."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","article-title":"Gepants for the treatment of migraine","volume":"28","author":"Negro","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/head.13529","article-title":"CGRP and the Trigeminal System in Migraine","volume":"59","author":"Iyengar","year":"2019","journal-title":"Headache"},{"key":"ref_59","first-page":"160","article-title":"Characterization of ubrogepant: A potent and selective antagonist of the human calcitonin gene-related peptide receptors","volume":"373","author":"Moore","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_60","unstructured":"Wattiez, A.S., Wang, M., and Russo, A.F. (2020, October 07). CGRP in animal models of migraine, Handbook of Experimental Pharmacology, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/30689086\/."},{"key":"ref_61","unstructured":"(2020, October 07). Allergan Enters into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program. Available online: https:\/\/www.prnewswire.com\/news-releases\/allergan-enters-into-licensing-agreement-with-merck-to-obtain-exclusive-worldwide-rights-to-cgrp-migraine-development-program-300109311.html."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/14737175.2020.1772758","article-title":"Targeting CGRP for migraine treatment: Mechanisms, antibodies, small molecules, perspectives","volume":"20","author":"Guglielmetti","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.13582","article-title":"Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review","volume":"59","author":"Chan","year":"2019","journal-title":"Headache"},{"key":"ref_64","unstructured":"Allergan, I. (2019). Ubrelvy, Allergan, Inc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cpt.1696","article-title":"Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial","volume":"107","author":"Jakate","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_66","first-page":"S8","article-title":"Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine","volume":"69","author":"Blumenfeld","year":"2020","journal-title":"J. Fam. Pract."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/0333102419869918","article-title":"Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0333102416653233","article-title":"A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","volume":"36","author":"Voss","year":"2016","journal-title":"Cephalalgia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The achieve ii randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA J. Am. Med. Assoc."}],"container-title":["Neurology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2035-8377\/13\/1\/4\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:16:21Z","timestamp":1760159781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2035-8377\/13\/1\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["neurolint13010004"],"URL":"https:\/\/doi.org\/10.3390\/neurolint13010004","relation":{},"ISSN":["2035-8377"],"issn-type":[{"type":"electronic","value":"2035-8377"}],"subject":[],"published":{"date-parts":[[2021,1,28]]}}}